MonkC
03-14
直接买下bio不就行了，我们虽然研究不出药，但是把强生，辉瑞，默沙东这些全款收购了，对于国内药业巨头来说也就几个碎银子吧
美知名组织BIO称正采取措施剔除药明康德会员资格，支持《生物安全法》
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
PandaPong
03-14
PandaPong
哈哈 你收购美国吧，反正我们的房产价值可以收购全世界了
亿千
03-14
亿千
牛逼，义乌小商品要收购英伟达呢
bojeckkk
03-14
bojeckkk
哈哈哈 有钱你就能买？
什么也没有了～
APP内打开
发表看法
3
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":284132629450760,"tweetId":"284132629450760","gmtCreate":1710384657872,"gmtModify":1710384660019,"author":{"id":3459684019883443,"authorId":3459684019883443,"authorIdStr":"3459684019883443","name":"MonkC","avatar":"https://static.tigerbbs.com/ec12067cba6bc73e116bdf4434f75837","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":7,"crmLevelSwitch":0,"individualDisplayBadges":[],"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>直接买下bio不就行了，我们虽然研究不出药，但是把强生，辉瑞，默沙东这些全款收购了，对于国内药业巨头来说也就几个碎银子吧</p></body></html>","htmlText":"<html><head></head><body><p>直接买下bio不就行了，我们虽然研究不出药，但是把强生，辉瑞，默沙东这些全款收购了，对于国内药业巨头来说也就几个碎银子吧</p></body></html>","text":"直接买下bio不就行了，我们虽然研究不出药，但是把强生，辉瑞，默沙东这些全款收购了，对于国内药业巨头来说也就几个碎银子吧","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/284132629450760","repostId":1139973071,"repostType":4,"repost":{"id":"1139973071","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1710384203,"share":"https://www.laohu8.com/m/news/1139973071?lang=&edition=full","pubTime":"2024-03-14 10:43","market":"hk","language":"zh","title":"美知名组织BIO称正采取措施剔除药明康德会员资格，支持《生物安全法》","url":"https://stock-news.laohu8.com/highlight/detail?id=1139973071","media":"老虎资讯综合","summary":"3月14日，今日在美国知名生物技术组织BIO（Biotechnology Innovation organization）官网获悉，BIO于美国时间3月13日发布一则新闻稿，称BIO目前正在采取措施，在组织成员资格方面与药明康德（WuXi-AppTec）分开，并表示将支持《生物安全法案》，并将随着该立法的进展与国会合作。在新闻稿中，BIO还透露其13日还致信众议院议员、美中战略竞争特别委员会主席迈克尔·加拉格尔（Michael Gallagher），表明其立场并强调生物技术行业对国家安全的重要性。小财注：药明康德曾是BIO长期会员，今日在医药股大涨情况下，药明系港股跌幅均在9%左右。","content":"<html><head></head><body><p>3月14日，今日在美国知名生物技术组织BIO（Biotechnology Innovation organization）官网获悉，BIO于美国时间3月13日发布一则新闻稿，称BIO目前正在采取措施，在组织成员资格方面与<a href=\"https://laohu8.com/S/603259\">药明康德</a>（WuXi-AppTec）分开，并表示将支持《生物安全法案》，并将随着该立法的进展与国会合作。在新闻稿中，BIO还透露其13日还致信众议院议员、美中战略竞争特别委员会主席迈克尔·加拉格尔（Michael Gallagher），表明其立场并强调生物技术行业对国家安全的重要性。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/44327aabce29b3b4e4bba028dfe35e1e\" title=\"\" tg-width=\"1192\" tg-height=\"486\"/></p><p>受此消息影响，今日港股药明系全线重挫，<a href=\"https://laohu8.com/S/02359\">药明康德</a>、<a href=\"https://laohu8.com/S/02269\">药明生物</a>、<a href=\"https://laohu8.com/S/02268\">药明合联</a>均跌超8%。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/236125c7a37ef46bc9043969be4ea5f9\" title=\"\" tg-width=\"560\" tg-height=\"240\"/></p><p></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a6a6142f58719d3b42e41a5728bcf261\" title=\"\" tg-width=\"560\" tg-height=\"240\"/></p><p></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ac291014da5e488a160c363039de6bfa\" title=\"\" tg-width=\"560\" tg-height=\"240\"/></p><p></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>美知名组织BIO称正采取措施剔除药明康德会员资格，支持《生物安全法》</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n美知名组织BIO称正采取措施剔除药明康德会员资格，支持《生物安全法》\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2024-03-14 10:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>3月14日，今日在美国知名生物技术组织BIO（Biotechnology Innovation organization）官网获悉，BIO于美国时间3月13日发布一则新闻稿，称BIO目前正在采取措施，在组织成员资格方面与<a href=\"https://laohu8.com/S/603259\">药明康德</a>（WuXi-AppTec）分开，并表示将支持《生物安全法案》，并将随着该立法的进展与国会合作。在新闻稿中，BIO还透露其13日还致信众议院议员、美中战略竞争特别委员会主席迈克尔·加拉格尔（Michael Gallagher），表明其立场并强调生物技术行业对国家安全的重要性。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/44327aabce29b3b4e4bba028dfe35e1e\" title=\"\" tg-width=\"1192\" tg-height=\"486\"/></p><p>受此消息影响，今日港股药明系全线重挫，<a href=\"https://laohu8.com/S/02359\">药明康德</a>、<a href=\"https://laohu8.com/S/02269\">药明生物</a>、<a href=\"https://laohu8.com/S/02268\">药明合联</a>均跌超8%。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/236125c7a37ef46bc9043969be4ea5f9\" title=\"\" tg-width=\"560\" tg-height=\"240\"/></p><p></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a6a6142f58719d3b42e41a5728bcf261\" title=\"\" tg-width=\"560\" tg-height=\"240\"/></p><p></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ac291014da5e488a160c363039de6bfa\" title=\"\" tg-width=\"560\" tg-height=\"240\"/></p><p></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","relate_stocks":{"603259":"药明康德","BK1583":"高瓴概念","LU2045819591.USD":"Natixis WCM Global Emerging Markets Equity R/A USD","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","BK4121":"生命科学工具和服务","BK4588":"碎股","LU2125910500.SGD":"Natixis WCM Global Emerging Markets Equity H-R/A SGD","BIO":"Bio Rad实验室","BK0216":"研究试验","LU0456842615.SGD":"JPMorgan Funds - Emerging Markets Equity A (acc) SGD","LU0052750758.USD":"富兰克林中国基金A Acc","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU1046422090.SGD":"Fidelity Pacific A-SGD","02359":"药明康德","02268":"药明合联","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","02269":"药明生物","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","BK4585":"ETF&股票定投概念","LU1997245177.USD":"安联神洲A股基金"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1139973071","content_text":"3月14日，今日在美国知名生物技术组织BIO（Biotechnology Innovation organization）官网获悉，BIO于美国时间3月13日发布一则新闻稿，称BIO目前正在采取措施，在组织成员资格方面与药明康德（WuXi-AppTec）分开，并表示将支持《生物安全法案》，并将随着该立法的进展与国会合作。在新闻稿中，BIO还透露其13日还致信众议院议员、美中战略竞争特别委员会主席迈克尔·加拉格尔（Michael Gallagher），表明其立场并强调生物技术行业对国家安全的重要性。受此消息影响，今日港股药明系全线重挫，药明康德、药明生物、药明合联均跌超8%。","news_type":1},"isVote":1,"tweetType":1,"viewCount":381,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":112,"xxTargetLangEnum":"ZH_CN"},"commentList":[{"id":284146849050696,"gmtCreate":1710388240721,"gmtModify":1710388244414,"authorId":3482988025047301,"author":{"id":3482988025047301,"authorId":3482988025047301,"name":"PandaPong","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":284132629450760,"type":1,"supId":0,"prevId":0,"content":"哈哈 你收购美国吧，反正我们的房产价值可以收购全世界了","text":"哈哈 你收购美国吧，反正我们的房产价值可以收购全世界了","html":"哈哈 你收购美国吧，反正我们的房产价值可以收购全世界了","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0},{"id":284133839310920,"gmtCreate":1710385064515,"gmtModify":1710385459606,"authorId":3566290818801808,"author":{"id":3566290818801808,"authorId":3566290818801808,"name":"亿千","avatar":"https://static.tigerbbs.com/b8074aa8994a90800980e41658344389","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":284132629450760,"type":1,"supId":0,"prevId":0,"content":"牛逼，义乌小商品要收购英伟达呢","text":"牛逼，义乌小商品要收购英伟达呢","html":"牛逼，义乌小商品要收购英伟达呢","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0},{"id":284135274963160,"gmtCreate":1710385395976,"gmtModify":1710385399683,"authorId":3482779624408181,"author":{"id":3482779624408181,"authorId":3482779624408181,"name":"bojeckkk","avatar":"https://static.tigerbbs.com/6e7b3cc7d8c77267b2fe513cfc5dec03","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":284132629450760,"type":1,"supId":0,"prevId":0,"content":"哈哈哈 有钱你就能买？","text":"哈哈哈 有钱你就能买？","html":"哈哈哈 有钱你就能买？","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/284132629450760"}
精彩评论